Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
PLIANT THERAPEUTICS, INC. (PLRX) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/03/2023 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Ob...
Docs: "LEASE AGREEMENT",
"TERMINATION"
08/09/2023 8-K Quarterly results
Docs: "Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results Initiation of Phase 2b BEACON-IPF trial of bexotegrast in patients with IPF"
06/08/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/09/2023 8-K Quarterly results
Docs: "Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results"
05/01/2023 8-K Quarterly results
03/09/2023 8-K Quarterly results
Docs: "Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2022 Financial Results"
03/08/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
02/23/2023 8-K Termination of a Material Definitive Agreement  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
01/25/2023 8-K Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Underwriting Agreement, by and among Pliant Therapeutics, Inc. and J.P. Morgan Securities LLC and Piper Sandler & Co., as representatives of the several underwriters named therein",
"Opinion of Sidley Austin LLP"
01/23/2023 8-K Other Events  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
01/23/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Pliant Therapeutics Announces Positive Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast 320 mg was Well Tolerated and Achieved Statistically Significant FVC Increase in Patients with Idiopathic Pulmonary Fibrosis"
01/09/2023 8-K Quarterly results
11/18/2022 8-K Quarterly results
11/08/2022 8-K Quarterly results
09/16/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Bylaws, as further amended and restated on September 14, 2022",
"Bylaws, as further amended and restated on September 14, 2022"
08/08/2022 8-K Quarterly results
07/14/2022 8-K Quarterly results
07/11/2022 8-K Quarterly results
06/17/2022 8-K Quarterly results
05/09/2022 8-K Quarterly results
Docs: "Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results"
02/28/2022 8-K Quarterly results
01/10/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Corporate Slide Presentation dated January 10, 2022, titled “Developing Novel Therapeutics for Fibrotic Diseases.”"
11/09/2021 8-K Quarterly results
Docs: "Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2021 Financial Results"
09/07/2021 8-K Quarterly results
08/09/2021 8-K Quarterly results
07/02/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
05/10/2021 8-K Quarterly results
03/16/2021 8-K Quarterly results
01/13/2021 8-K Quarterly results
12/21/2020 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
Docs: "Amended and Restated Bylaws of Pliant Therapeutics, Inc.",
"Amended and Restated Bylaws of Pliant Therapeutics, Inc."
11/10/2020 8-K Quarterly results
Docs: "Enrollment of Phase 2a 12-week trials of PLN-74809 in idiopathic pulmonary fibrosis and primary sclerosing cholangitis progressing. After resuming enrollment earlier in the year, Pliant has remained in close coordination with its global trial sites in order to facilitate enrollment in both Phase 2a trials. The Company also continues to open additional trial sites as COVID-19 related restrictions are eased. The hybrid approach to clinical trial participation utilizing home-health solutions to maximize patient safety is expected to aid in trial recruitment. • Phase 2a PET imaging trial of PLN-74809 in IPF is enrolling. The Phase 2a PET trial will evaluate safety, tolerability, and target engagement of PLN-74809 in IPF patients. We expect to report preliminary data by the first half of..."
08/11/2020 8-K Quarterly results

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy